天津科学技术出版社

克拉屈滨联合低剂量阿糖胞苷和粒细胞集落刺激因子治疗老年/无法耐受强化疗的难治/复发急性髓系白血病

周乔依 1,2 #,刘宏 1,2 #,吴立华 1,2,刘春华 1,2,王夕妍 1,2,王珍珍 1,2,顾闰夏 1,2,魏述宁 1,2,王迎 1,2,3 *
作者信息
  1. 1 北京协和医学院中国医学科学院血液病医院(中国医学科学院血液学研究所),天津 300020
  2. 2 血液与健康全国重点实验室,天津 300020
  3. 3 天津医学健康研究所,天津 301600
#共同第一作者
*通信作者

摘要

目的 克拉屈滨+阿糖胞苷+粒细胞集落刺激因子(CLAG)为难治/复发急性髓系白血病(R/R AML)患者的一线挽救治疗方案之一,然而其毒性限制了其在老年/无法耐受强化疗患者中的应用。 因此,尝试采用低剂量阿糖胞苷+克拉屈滨+粒细胞集落刺激因子(miniCLAG)治疗老年/无法耐受强化疗的 R/R AML 患者。 方法 回顾性分析2022 年 8 月至 2025 年 4 月接受 miniCLAG 方案治疗的 16 例老年/无法耐受强化疗的R/R AML 患者的临床资料。 所有患者均接受至少1个疗程的 miniCLAG 治疗并评估了骨髓和生存状态。 方案组成为克拉屈滨 5 mg/m2,第 1 ~ 5 天静脉输注;阿糖胞苷20 mg每12h一次,第1~10天皮下注射;粒细胞集落刺激因子(G-CSF)300μg/d,第0~10天皮下注射(白细胞计数>20×109/L时停用)。 结果 患者中位年龄为 60 岁,50% 的患者逸60 岁。完全缓解/完全缓解伴不完全血液学恢复(CR/ CRi)率为 37. 5% ,无治疗相关死亡。 中位总生存期未达到,估计 1 年总生存率为 85. 94% [95% 置信区间(CI):69. 49% ~ 100% ]。中位无复发生存期为 293 d(95% CI:246d~NA)。 不携带核心结合因子融合蛋白的 AML 患者在该方案下获得了更长的总生存期。 结论 miniCLAG方案可为老年/无法耐受强化疗的 R/R AML 患者提供一定的疗效且毒副反应较小,尤其适用于不携带核心结合因子融合蛋白的患者。

Cladribine combined with low-dose cytarabine and granulocyte colony-stimulating factor in older/unfit refractory/relapsed acute myeloid leukemia

Qiaoyi ZHOU 1,2 #, Hong LIU 1,2 #, Lihua WU 1,2, Chunhua LIU 1,2, Xiyan WANG 1,2, Zhenzhen WANG 1,2, Runxia GU 1,2, Shuning WEI 1,2, Ying WANG 1,2,3 *
Author Information
  1. 1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin 300020, China
  2. 2 State Key Laboratory of Experimental Hematology, Tianjin 300020, China
  3. 3 Tianjin Institute of Health Science, Tianjin 301600, China
#Co-first author
*Corresponding author

Abstract

Objective CLAG (cladribine+cytarabine+granulocyte colony-stimulating factor) is recommended as one of the first-line salvage treatment for refractory/relapsed acute myeloid leukemia (R/R AML) patients. However, the toxicity limits its usage in older and unfit patients. Thus, we explored the feasibility of the regimen consisting of cladribine, low-dose cytarabine and granulocyte colony-stimulating factor (miniCLAG) in unfit R/R AML patients. Methods 16 older/ unfit R/R AML patients treated with the miniCLAG regimen from August 2022 to April 2025 were retrospectively analyzed. All of them received at least one course of miniCLAG. The regimen comprised cladribine 5 mg/m2 from day 1 to day 5 intravenously, cytarabine 20 mg q12h from day 1 to day 10 subcutaneously and granulocyte colony-stimulating factor (G-CSF) 300 μg/d from day 0 to day 10 subcutaneously (discontinued if WBC >20×109/L). Results The median age of our cohort was 60 years old with 50% aged 60 or older. The complete remission (CR)/CR with incomplete hematologic recovery (CRi) rate was 37. 5% , without treatment-related death. The median overall survival wasn't reached and the estimated 1-year overall survival was 85. 94% [95% confidence interval (CI): 69. 49%~100%]. The median relapse-free survival was 293 days (95% CI: 246 days-NA). AML without core-binding factor fusion protein gained longer overall survival under this regimen. Conclusion The miniCLAG regimen may provide considerable efficacy with acceptable toxicity to the refractory/relapsed unfit AML patients, especially for those without core-binding factor fusion protein.

再生医学研究 Copyright © 2026. All Rights Reserved